Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Campath following Tacrolimus monotherapy is
more effective in the prevention of renal graft rejection (considering an acute rejection
rate of 5% for Campath-1H/Tacrolimus and of 22% for Tacrolimus/MMF/Steroids).